Research Analysts Set Expectations for argenex Q1 Earnings

Key Points

• William Blair increased their Q1 2026 earnings per share (EPS) estimate for argenex to $6.46, up from a previous forecast of $4.77, reflecting positive expectations for the company's growth.
• The consensus estimate for argenex's full-year earnings has been reported at $3.13 per share, with Q2, Q3, and Q4 earnings also projected to rise significantly throughout 2026.
• Despite a recent stock price adjustment, argenex maintains a strong analyst consensus rating of "Buy" with a target price of $789.20, indicating confidence in its future performance.

argenex SE (NASDAQ:ARGX - Free Report) - Investment analysts at William Blair increased their Q1 2026 earnings estimates for shares of argenex in a research report issued on Wednesday, September 17th. William Blair analyst M. Minter now anticipates that the company will post earnings of $6.46 per share for the quarter, up from their prior forecast of $4.77. The consensus estimate for argenex's current full-year earnings is $3.13 per share. William Blair also issued estimates for argenex's Q2 2026 earnings at $7.20 EPS, Q3 2026 earnings at $8.70 EPS and Q4 2026 earnings at $9.53 EPS.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley upped their price target on shares of argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Guggenheim reiterated a "buy" rating and issued a $1,070.00 price objective on shares of argenex in a research note on Thursday, September 18th. Bank of America upped their price objective on shares of argenex from $880.00 to $887.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Wells Fargo & Company upped their price objective on shares of argenex from $741.00 to $756.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of argenex from a "buy" rating to a "hold" rating in a research note on Thursday, September 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $789.20.

argenex Price Performance

Shares of NASDAQ ARGX traded down $0.34 during mid-day trading on Friday, reaching $739.69. 54,833 shares of the company traded hands, compared to its average volume of 375,989. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $779.03. The firm has a market cap of $45.27 billion, a PE ratio of 37.93, a price-to-earnings-growth ratio of 0.80 and a beta of 0.41. The stock has a fifty day simple moving average of $672.28 and a 200-day simple moving average of $611.94.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The firm had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million.

Hedge Funds Weigh In On argenex

Several large investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC grew its stake in shares of argenex by 203.7% in the second quarter. Valeo Financial Advisors LLC now owns 1,303 shares of the company's stock valued at $718,000 after acquiring an additional 874 shares in the last quarter. Orion Porfolio Solutions LLC grew its stake in argenex by 17.8% during the second quarter. Orion Porfolio Solutions LLC now owns 10,294 shares of the company's stock worth $5,674,000 after buying an additional 1,558 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in argenex by 6.9% during the second quarter. Thrivent Financial for Lutherans now owns 527 shares of the company's stock worth $295,000 after buying an additional 34 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in argenex during the second quarter worth about $37,441,000. Finally, Tower Research Capital LLC TRC grew its stake in argenex by 257.9% during the second quarter. Tower Research Capital LLC TRC now owns 19,339 shares of the company's stock worth $10,660,000 after buying an additional 13,935 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.